Stock News

Sarepta Therapeutics, Inc. (SRPT) Reaches $91.83 After 4.00% Down Move; Masco (MAS) Covered By 15 Bulls

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo

The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a huge mover today! The stock decreased 2.26% or $2.12 during the last trading session, reaching $91.83. About 734,476 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 149.90% since May 17, 2017 and is uptrending. It has outperformed by 138.35% the S&P500.The move comes after 8 months negative chart setup for the $6.02 billion company. It was reported on May, 17 by Barchart.com. We have $88.16 PT which if reached, will make NASDAQ:SRPT worth $240.72 million less.

Among 25 analysts covering Masco (NYSE:MAS), 15 have Buy rating, 0 Sell and 10 Hold. Therefore 60% are positive. Masco had 72 analyst reports since July 28, 2015 according to SRatingsIntel. The company was downgraded on Friday, January 5 by JP Morgan. RBC Capital Markets maintained the shares of MAS in report on Wednesday, April 26 with “Outperform” rating. The rating was maintained by Barclays Capital with “Overweight” on Wednesday, October 25. The stock of Masco Corporation (NYSE:MAS) has “Buy” rating given on Wednesday, January 17 by Jefferies. The firm earned “Buy” rating on Monday, May 14 by Wells Fargo. On Thursday, April 6 the stock rating was upgraded by Longbow to “Buy”. The rating was initiated by Goldman Sachs with “Buy” on Tuesday, October 6. The firm earned “Buy” rating on Thursday, March 22 by Deutsche Bank. The firm earned “Outperform” rating on Friday, January 22 by Robert W. Baird. RBC Capital Markets maintained it with “Buy” rating and $46.0 target in Friday, February 9 report. See Masco Corporation (NYSE:MAS) latest ratings:

14/05/2018 Broker: Wells Fargo Rating: Buy New Target: $45.0000 Upgrade
14/05/2018 Broker: Bank of America Rating: Hold New Target: $44.0000 Downgrade
26/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $49 New Target: $45 Maintain
25/04/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $48 New Target: $47 Maintain
25/04/2018 Broker: RBC Capital Markets Rating: Buy New Target: $43.0000 Maintain
25/04/2018 Broker: Gabelli Old Rating: Hold New Rating: Buy Upgrade
25/04/2018 Broker: Credit Suisse Old Rating: Neutral New Rating: Neutral Old Target: $46 New Target: $40 Maintain
24/04/2018 Broker: FBR Capital Rating: Buy New Target: $46.0000 Maintain
24/04/2018 Broker: Robert W. Baird Rating: Buy New Target: $46.0000 Maintain
13/04/2018 Broker: Argus Research Rating: Buy New Target: $50.0000

Analysts await Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report earnings on July, 18. They expect $-0.57 EPS, up 50.43% or $0.58 from last year’s $-1.15 per share. After $-0.44 actual EPS reported by Sarepta Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 29.55% negative EPS growth.

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. Sarepta Therapeutics had 118 analyst reports since August 5, 2015 according to SRatingsIntel. Oppenheimer maintained the shares of SRPT in report on Thursday, July 20 with “Buy” rating. The firm has “Buy” rating given on Monday, October 9 by Leerink Swann. The stock has “Buy” rating by SunTrust on Thursday, March 15. SunTrust downgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Tuesday, April 26. SunTrust has “Reduce” rating and $4 target. Wedbush maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Monday, October 10. Wedbush has “Outperform” rating and $72 target. The firm has “Overweight” rating by JP Morgan given on Thursday, December 22. The firm has “Buy” rating given on Thursday, October 26 by Needham. As per Tuesday, September 12, the company rating was maintained by Cowen & Co. The rating was maintained by TH Capital on Wednesday, August 26 with “Buy”. The rating was maintained by Roth Capital with “Buy” on Thursday, August 20.

Investors sentiment decreased to 1.22 in Q4 2017. Its down 1.66, from 2.88 in 2017Q3. It worsened, as 27 investors sold Sarepta Therapeutics, Inc. shares while 67 reduced holdings. 45 funds opened positions while 70 raised stakes. 52.88 million shares or 2.28% more from 51.70 million shares in 2017Q3 were reported. Camber Capital Mgmt Ltd Liability Corporation invested 0.82% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Pictet Asset Mngmt, a United Kingdom-based fund reported 40,200 shares. Private Ocean Limited Company holds 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) or 200 shares. Legal And General Grp Public Limited Company invested in 26,363 shares or 0% of the stock. Pnc Fincl Ser Gp Inc reported 134,314 shares. Aperio Lc stated it has 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Alyeska Invest Gp Limited Partnership reported 1.05 million shares. Winslow Evans Crocker holds 1,000 shares. Pub Employees Retirement Association Of Colorado has 10,545 shares. Moreover, Capital Fund has 0.02% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Raymond James & Assoc has 24,353 shares for 0% of their portfolio. Glenmede Na holds 0% or 2,300 shares in its portfolio. 1,200 were reported by Mutual Of America Capital Mgmt Ltd Liability Com. Etrade Capital Limited Liability stated it has 4,434 shares or 0.01% of all its holdings. Mark Sheptoff Finance Planning Ltd Llc accumulated 100 shares.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $6.02 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Seekingalpha.com which released: “The Market Has Spoken: Buy Sarepta” on May 07, 2018, also Nasdaq.com with their article: “Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene …” published on May 03, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on May 11, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Nasdaq.com and their article: “Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)” published on April 30, 2018 as well as Investorplace.com‘s news article titled: “7 ‘Strong Buy’ Stocks Analysts Are Upgrading Now” with publication date: May 14, 2018.

Masco Corporation designs, manufactures, markets, and distributes home improvement and building products worldwide. The company has market cap of $11.70 billion. The Company’s Plumbing Products segment provides faucets, showerheads, handheld showers, valves, bathing units, shower enclosures, toilets, acrylic tubs, shower trays, spas products, exercise pools and systems, brass and copper plumbing system components, and other non-decorative plumbing products. It has a 22.69 P/E ratio. The companyÂ’s Decorative Architectural Products segment offers architectural coatings, including paints, primers, specialty paints, stains, and waterproofing products; cabinet, door, window, and hardware products; and functional hardware, wall plates, hook and rail products, and picture hanging accessories, as well as decorative bath hardware, shower accessories, and shower doors.

Investors sentiment increased to 1 in Q4 2017. Its up 0.02, from 0.98 in 2017Q3. It improved, as 26 investors sold Masco Corporation shares while 199 reduced holdings. 77 funds opened positions while 149 raised stakes. 272.45 million shares or 1.07% less from 275.40 million shares in 2017Q3 were reported. Vnbtrust Natl Association has 0.14% invested in Masco Corporation (NYSE:MAS) for 5,300 shares. Cambridge Grp Inc holds 3.75% of its portfolio in Masco Corporation (NYSE:MAS) for 172,974 shares. Palisade Capital Mgmt Limited Liability Company Nj invested 0.01% of its portfolio in Masco Corporation (NYSE:MAS). Johnson Fincl Grp Incorporated reported 363 shares or 0% of all its holdings. Nomura Asset reported 44,486 shares. Tarbox Family Office holds 0% or 237 shares. Marshwinds Advisory reported 18,300 shares. 99,204 are owned by Amp Capital Invsts. Campbell And Invest Adviser Lc accumulated 6,788 shares. Point72 Asia (Hong Kong) Limited has invested 0.02% in Masco Corporation (NYSE:MAS). Clinton Grp reported 126,749 shares stake. Spirit Of America Management holds 0.06% or 11,500 shares. Janney Montgomery Scott Limited Liability Company holds 18,030 shares. Broadview Advsrs Limited Com reported 1.26% of its portfolio in Masco Corporation (NYSE:MAS). Liberty Mutual Gp Asset Mgmt reported 0.02% of its portfolio in Masco Corporation (NYSE:MAS).

Since February 21, 2018, it had 0 insider purchases, and 6 insider sales for $6.69 million activity. On Monday, March 12 the insider MANOOGIAN RICHARD A sold $2.00 million. On Tuesday, February 27 LOSH J MICHAEL sold $234,989 worth of Masco Corporation (NYSE:MAS) or 5,592 shares. VAN LOKEREN MARY ANN had sold 5,654 shares worth $241,844 on Monday, March 12. Gross Joseph B. also sold $438,219 worth of Masco Corporation (NYSE:MAS) on Friday, February 23. Shares for $233,405 were sold by PAYNE LISA A.

The stock decreased 0.63% or $0.24 during the last trading session, reaching $37.67. About 1.63 million shares traded. Masco Corporation (NYSE:MAS) has risen 19.95% since May 17, 2017 and is uptrending. It has outperformed by 8.40% the S&P500.

Masco Corporation (NYSE:MAS) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *